Symbols / OCEA
OCEA Chart
About
Ocean Biomedical, Inc., a biopharmaceutical company, focuses on discovering and developing therapeutic products in oncology, fibrosis, and infectious diseases in the United States. The company's oncology product candidates include OCX-253 anti-Chi3l1 Single-target mAb and OCX-410 anti-Chi3l1/PD-1 Bi-specific antibody for the treatment of non-small cell lung cancer; and OCX-909 anti-Chi3l1/CTLA-4 Bi-specific antibody to treat glioblastoma multiforme. Its fibrosis product candidates consist of OCF-203 anti-Chit1 small molecule for the treatment of idiopathic pulmonary fibrosis (IPF) and hermansky-pudlak syndrome (HPS). The company's infectious diseases product candidates for malaria include the ODA-570 vaccine for the prevention of P. falciparum infection; ODA-611 anti-PfGARP mAb for the treatment of Symptomatic P. falciparum infection; and ODA-579 anti-PfGARP small molecule for the treatment of Symptomatic P. falciparum infection. It has license agreement with Elkurt, Inc. for FRG Antibody, bi-specific antibody anti-CTLA4, bispecific (FRG)x anti-PD-1 (FRGxPD-1), chit1 small molecule antifibrotic, and malaria small molecules and antibodies. The company was founded in 2019 and is based in Providence, Rhode Island. Ocean Biomedical, Inc. is a subsidiary of Poseidon Bio, LLC.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 325.31K |
| Enterprise Value | — | Income | -30.72M | Sales | — |
| Book/sh | -0.56 | Cash/sh | — | Dividend Yield | — |
| Payout | 0.00% | Employees | 7 | IPO | — |
| P/E | — | Forward P/E | -0.00 | PEG | — |
| P/S | — | P/B | -0.00 | P/C | — |
| EV/EBITDA | — | EV/Sales | — | Quick Ratio | — |
| Current Ratio | 0.06 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -0.91 | EPS next Y | -0.89 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2024-04-15 17:00 | ROA | -114.87% |
| ROE | — | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 232.37M |
| Shs Float | 208.41M | Short Float | 2.05% | Short Ratio | 0.05 |
| Short Interest | — | 52W High | 0.16 | 52W Low | 0.00 |
| Beta | 1.49 | Avg Volume | 175.68K | Volume | 7.78K |
| Target Price | — | Recom | None | Prev Close | $0.00 |
| Price | $0.00 | Change | -17.65% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
—
Mean price target
2. Current target
$0.00
Latest analyst target
3. DCF / Fair value
$-0.41
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.00
Low
—
High
—
Mean
—
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2023-05-31 | init | Taglich Brothers | — → Speculative Buy | $20 |
| 2023-04-27 | main | EF Hutton | — → Buy | $17 |
| 2023-04-13 | reit | EF Hutton | — → Buy | $10 |
| 2023-03-16 | init | Fundamental Research Corp. | — → Buy | $16 |
| 2023-03-13 | init | EF Hutton | — → Buy | $10 |
- Ocean Biomedical Reveals Dramatic Business Transformation: Biotech Giant Expands into Energy and Digital Assets - Stock Titan ue, 22 Apr 2025 07
- Ocean Biomedical to be delisted from Nasdaq following appeal denial - Investing.com Wed, 23 Jul 2025 07
- Ocean Biomedical stock plunges to 52-week low of $0.04 - Investing.com ue, 08 Apr 2025 07
- Four board members to exit troubled RI biotech - The Business Journals hu, 27 Mar 2025 07
- Ocean Biomedical Faces Nasdaq Non-Compliance Notice and Delays - Nasdaq hu, 30 May 2024 07
- 3 Growth Stocks To Make You The Millionaire Next Door: October Edition - InvestorPlace Wed, 11 Oct 2023 07
- Ocean Biomedical Inc Com (OCEA) reports earnings - qz.com Mon, 13 Jan 2025 08
- Ocean Biomedical Announces Breakthrough Findings in EGFR-Mutant Lung Cancer and Plans for FDA Alignment on Next-Stage Development - GlobeNewswire Mon, 10 Feb 2025 08
- Ocean Biomedical, Inc. Announces Receipt of Nasdaq Staff Determination Letter - Stock Titan ue, 22 Oct 2024 07
- Ocean Biomedical stock plunges to 52-week low of $0.07 - Investing.com hu, 13 Mar 2025 07
- Ocean Biomedical faces license terminations over breaches - Investing.com Sat, 14 Jun 2025 07
- OCEA - Ocean Biomedical Inc. Latest Stock News & Market Updates - Stock Titan Fri, 18 Jun 2021 04
- Ocean Biomedical licenses with Elkurt terminated following breach notice - Investing.com Wed, 16 Jul 2025 07
- Ocean Biomedical announces board reshuffle amid resignations - Investing.com Mon, 10 Mar 2025 07
- Ocean Biomedical stock plunges to 52-week low of $0.04 - Investing.com hu, 17 Apr 2025 07
Insider Transactions
No recent insider transactions.
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -3.54M | -12.44M | -16.12M | -62.34M |
| TotalUnusualItems | -3.89M | -100.26M | 0.00 | |
| TotalUnusualItemsExcludingGoodwill | -3.89M | -100.26M | 0.00 | |
| NetIncomeFromContinuingOperationNetMinorityInterest | -9.48M | -114.47M | -17.36M | -62.34M |
| EBITDA | -7.43M | -112.70M | -16.12M | -62.34M |
| EBIT | -7.43M | -112.70M | -16.12M | -62.34M |
| NetInterestIncome | -2.05M | -1.76M | -1.24M | |
| InterestExpense | 2.05M | 1.76M | 1.24M | |
| InterestIncome | 1.52M | |||
| NormalizedIncome | -5.59M | -14.20M | -17.36M | -62.34M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -9.48M | -114.47M | -17.36M | -62.34M |
| TotalExpenses | 3.80M | 10.21M | 16.12M | 62.34M |
| TotalOperatingIncomeAsReported | -3.80M | -10.21M | -16.12M | -62.34M |
| DilutedAverageShares | 27.50M | 26.29M | 36.50M | 20.20M |
| BasicAverageShares | 27.50M | 26.29M | 36.50M | 20.20M |
| DilutedEPS | -0.34 | -4.35 | -0.86 | -3.09 |
| BasicEPS | -0.34 | -4.35 | -0.86 | -3.09 |
| DilutedNIAvailtoComStockholders | -9.48M | -114.47M | -17.36M | -62.34M |
| NetIncomeCommonStockholders | -9.48M | -114.47M | -17.36M | -62.34M |
| NetIncome | -9.48M | -114.47M | -17.36M | -62.34M |
| NetIncomeIncludingNoncontrollingInterests | -9.48M | -114.47M | -17.36M | -62.34M |
| NetIncomeContinuousOperations | -9.48M | -114.47M | -17.36M | -62.34M |
| PretaxIncome | -9.48M | -114.47M | -17.36M | -62.34M |
| OtherIncomeExpense | -3.64M | -102.49M | 5.00K | 1.00K |
| OtherNonOperatingIncomeExpenses | 3.56M | -1.52M | 5.00K | 1.00K |
| SpecialIncomeCharges | -356.00K | -36.49M | 0.00 | |
| OtherSpecialCharges | 15.08M | |||
| RestructuringAndMergernAcquisition | 356.00K | 21.41M | 0.00 | |
| EarningsFromEquityInterest | -3.30M | -708.00K | ||
| GainOnSaleOfSecurity | -3.54M | -63.78M | ||
| NetNonOperatingInterestIncomeExpense | -2.05M | -1.76M | -1.24M | |
| InterestExpenseNonOperating | 2.05M | 1.76M | 1.24M | |
| InterestIncomeNonOperating | 1.52M | |||
| OperatingIncome | -3.80M | -10.21M | -16.12M | -62.34M |
| OperatingExpense | 3.80M | 10.21M | 16.12M | 62.34M |
| OtherOperatingExpenses | 2.48M | |||
| ResearchAndDevelopment | 26.00K | 709.00K | 8.41M | 33.93M |
| SellingGeneralAndAdministration | 3.77M | 9.51M | 7.71M | 28.41M |
| GeneralAndAdministrativeExpense | 3.77M | 9.51M | 7.71M | 28.41M |
| OtherGandA | 3.77M | 9.51M | 7.71M | 28.41M |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 34.87M | 34.65M | 33.77M | 20.20M |
| ShareIssued | 34.87M | 34.65M | 33.77M | 20.20M |
| NetDebt | 16.30M | 12.11M | 742.00K | |
| TotalDebt | 16.30M | 12.12M | 776.00K | |
| TangibleBookValue | -97.62M | -90.76M | -10.82M | 105.26M |
| InvestedCapital | -81.32M | -78.64M | -10.04M | 105.26M |
| WorkingCapital | -33.08M | -27.90M | -10.82M | 1.30M |
| NetTangibleAssets | -97.62M | -90.76M | -10.82M | 105.26M |
| CommonStockEquity | -97.62M | -90.76M | -10.82M | 105.26M |
| TotalCapitalization | -97.62M | -90.76M | -10.82M | 105.26M |
| TotalEquityGrossMinorityInterest | -97.62M | -90.76M | -10.82M | 105.26M |
| StockholdersEquity | -97.62M | -90.76M | -10.82M | 105.26M |
| RetainedEarnings | -205.53M | -196.06M | -81.59M | -564.11K |
| AdditionalPaidInCapital | 107.92M | 105.29M | 70.77M | -1.28M |
| CapitalStock | 0.00 | 0.00 | 0.00 | 107.10M |
| CommonStock | 0.00 | 0.00 | 0.00 | 107.10M |
| PreferredStock | 0.00 | 0.00 | ||
| TotalLiabilitiesNetMinorityInterest | 98.52M | 96.26M | 12.66M | 3.40M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 64.63M | 66.25M | 0.00 | 3.15M |
| OtherNonCurrentLiabilities | 5.57M | 7.73M | ||
| DerivativeProductLiabilities | 59.06M | 58.52M | 0.00 | |
| NonCurrentDeferredLiabilities | 3.15M | 3.15M | ||
| CurrentLiabilities | 33.89M | 30.01M | 12.66M | 246.44K |
| OtherCurrentLiabilities | 1.09M | 763.00K | ||
| CurrentDebtAndCapitalLeaseObligation | 16.30M | 12.12M | 776.00K | |
| CurrentDebt | 16.30M | 12.12M | 776.00K | |
| OtherCurrentBorrowings | 14.07M | 8.32M | 776.00K | |
| CurrentNotesPayable | 2.23M | 3.80M | ||
| PayablesAndAccruedExpenses | 16.50M | 17.13M | 11.88M | 246.44K |
| CurrentAccruedExpenses | 15.70M | 16.20M | 11.88M | 212.00K |
| Payables | 799.00K | 933.00K | 324.83K | 34.44K |
| AccountsPayable | 799.00K | 933.00K | 0.00 | 34.44K |
| TotalAssets | 902.00K | 5.50M | 1.84M | 108.65M |
| TotalNonCurrentAssets | 90.00K | 3.39M | 0.00 | 107.10M |
| OtherNonCurrentAssets | 110.44M | 107.10M | ||
| InvestmentsAndAdvances | 90.00K | 3.39M | 0.00 | |
| CurrentAssets | 812.00K | 2.11M | 1.84M | 1.55M |
| CurrentDeferredAssets | 0.00 | 1.81M | 19.00K | |
| RestrictedCash | 224.00K | 1.00M | 0.00 | |
| PrepaidAssets | 588.00K | 1.10M | 0.00 | 474.29K |
| Receivables | 50.00K | 0.00 | ||
| DuefromRelatedPartiesCurrent | 50.00K | 0.00 | ||
| CashCashEquivalentsAndShortTermInvestments | 0.00 | 4.00K | 34.00K | 1.08M |
| CashAndCashEquivalents | 0.00 | 4.00K | 34.00K | 1.08M |
| CashFinancial | 0.00 | 4.00K | 34.00K | 1.08M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -4.18M | -9.43M | -993.00K | -1.05M |
| RepurchaseOfCapitalStock | 0.00 | -64.28M | 0.00 | |
| RepaymentOfDebt | 0.00 | -2.10M | 0.00 | |
| IssuanceOfDebt | 3.40M | 8.91M | 735.00K | |
| IssuanceOfCapitalStock | 0.00 | 15.77M | 0.00 | 1.02M |
| EndCashPosition | 224.00K | 1.00M | 34.00K | 60.00K |
| BeginningCashPosition | 1.00M | 34.00K | 60.00K | 0.00 |
| ChangesInCash | -780.00K | 970.00K | -26.00K | 60.00K |
| FinancingCashFlow | 3.40M | 10.40M | 967.00K | 1.11M |
| CashFlowFromContinuingFinancingActivities | 3.40M | 10.40M | 967.00K | 1.11M |
| NetOtherFinancingCharges | 52.10M | 232.00K | 96.00K | |
| ProceedsFromStockOptionExercised | 0.00 | |||
| NetCommonStockIssuance | 0.00 | -48.51M | 0.00 | 1.02M |
| CommonStockPayments | 0.00 | -64.28M | 0.00 | |
| CommonStockIssuance | 0.00 | 15.77M | 0.00 | 1.02M |
| NetIssuancePaymentsOfDebt | 3.40M | 6.81M | 735.00K | |
| NetShortTermDebtIssuance | 0.00 | 6.16M | 735.00K | |
| ShortTermDebtPayments | 0.00 | -2.10M | 0.00 | |
| ShortTermDebtIssuance | 0.00 | 8.26M | 735.00K | |
| NetLongTermDebtIssuance | 3.40M | 650.00K | 0.00 | |
| LongTermDebtPayments | 0.00 | |||
| LongTermDebtIssuance | 3.40M | 650.00K | 0.00 | |
| InvestingCashFlow | -2.10M | 0.00 | ||
| CashFlowFromContinuingInvestingActivities | -2.10M | |||
| NetOtherInvestingChanges | -2.10M | |||
| OperatingCashFlow | -4.18M | -9.43M | -993.00K | -1.05M |
| CashFlowFromContinuingOperatingActivities | -4.18M | -9.43M | -993.00K | -1.05M |
| ChangeInWorkingCapital | 1.04M | 1.18M | 2.81M | 4.74M |
| ChangeInPayablesAndAccruedExpense | 526.00K | 1.70M | 2.81M | |
| ChangeInAccruedExpense | -343.00K | 467.00K | 0.00 | |
| ChangeInPayable | 869.00K | 1.23M | 2.81M | |
| ChangeInAccountPayable | 869.00K | 1.23M | 2.81M | |
| ChangeInPrepaidAssets | 517.00K | -519.00K | 384.61K | |
| OtherNonCashItems | -3.33M | 15.51M | 929.00K | |
| StockBasedCompensation | 745.00K | 1.21M | 12.38M | 56.55M |
| UnrealizedGainLossOnInvestmentSecurities | 1.47M | -1.17M | 0.00 | |
| OperatingGainsLosses | 5.37M | 88.31M | 250.00K | |
| EarningsLossesFromEquityInvestments | 3.30M | 708.00K | 0.00 | |
| GainLossOnInvestmentSecurities | 1.98M | 64.95M | 250.00K | |
| NetForeignCurrencyExchangeGainLoss | 85.00K | 0.00 | ||
| GainLossOnSaleOfBusiness | 0.00 | 7.58M | 0.00 | |
| NetIncomeFromContinuingOperations | -9.48M | -114.47M | -17.36M | -62.34M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for OCEA
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|